Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign

The campaign places renewed focus on a disease that remains incurable despite major scientific advances

Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%

MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease

Lilly brings heavy oncology firepower to ASCO with plenary data across cancers

The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy

Bristol Myers Squibb to unveil massive oncology data push at ASCO 2026

The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”

AbbVie signals major oncology momentum at ASCO

With standout ADC and t-cell engager response data across hard-to-treat cancers

Venus Remedies secures global approval for Plerixafor in Saudi Arabia

SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region

Gilead completes $7.8B Arcellx acquisition & takes full control of Myeloma CAR-T candidate

Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right

Pfizer drug delivers breakthrough in late-stage blood cancer trial

Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Middle East disruption hits thousands of global clinical trials, Phesi warns

The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment